News for Skye Bioscience, Inc. (SKYE)

SAN DIEGO, May 22, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. ( SKYE) (”œSkye”), a clinical-stage biotechnology company focused on unlocking new therap

Proprietary formulation technology being applied to potentially enhance properties of nimacimab SAN DIEGO, May 19, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience,

Skye Bioscience (SKYE) partners with Arecor Therapeutics to develop an enhanced formulation of obesity drug nimacimab using Arestatâ„¢ technology. Nimac

SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. ( SKYE) (”œSkye”), a clinical-stage biopharmaceutical company focused on unlocking new th

Oppenheimer has revised its price target for Skye Bioscience (SKYE), bringing it down from $21 to $17, while maintaining an Outperform rating. The adjustment fo

Skye Bioscience, Inc. (NASDAQ:SKYE) Q1 2025 Earnings Conference Call May 9, 2025 4:30 PM ETCompany ParticipantsBernie Hertel - Head of Investor...

The following slide deck was published by Skye Bioscience, Inc.

Release Date: May 08, 2025For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Skye Bioscience I

Refinitiv StreetEvents Event TranscriptE D I T E D V E R S I O NSKYE.OQ - Skye Bioscience IncQ1 2025 Skye Bioscience Inc Earnings CallMay 08, 2025 / 08:30PM G

Nimacimab in combination with tirzepatide improves weight loss effect over tirzepatide alone, and shows comparable weight loss to monlunabant and tirzepatide al

U.S. stocks traded higher midway through trading, with the Dow Jones index gaining around 50 points on Tuesday. The Dow traded up 0.17% to 40,592.77 while the ...

U.S. stocks traded higher this morning, with the Nasdaq Composite gaining around 100 points on Tuesday. Following the market opening Tuesday, the Dow traded up...

Skye Bioscience, under the ticker SKYE, has unveiled promising preclinical results for its innovative CB1 antibody, nimacimab. In a study examining diet-induced

Skye Bioscience (SKYE), a clinical-stage biopharmaceutical company, will attend the Piper Sandler Spring Biopharma Symposium. The event will be held on

**media[594185]**

Operator: Ladies and gentlemen, thank you for standing by. My name is Jale, and I will be your conference operator today.

Skye Bioscience, Inc. (NASDAQ:SKYE) Q4 2024 Earnings Conference Call March 20, 2025 4:30 PM ETCompany ParticipantsBernie Hertel - Head of Investor...

Enrollment completed in Phase 2a CBeyondâ„¢ trial of CB1 inhibitor, nimacimab, in obesity and overweightFaster-than-expected enrollment enables full top-line Ph

**media[572469]**